96420-5
Daratumumab [Presence] in Serum by Immunofixation
Active
Term Description
Daratumumab is a monoclonal antibody used to treat multiple myeloma, which is, itself, a disease that results in antibody overproduction, shown as M protein band in immunoelectrophoresis. Daratumumab, the treatment, can show up as part of the M spike and interfere with the assay for the M-protein in multiple myeloma. An antibody against Daratumumab can be added to the assay, which shifts the Daratumumab band, allowing the Daratumumab band to be distinguished from the M-protein band and reported separately.
Source: Regenstrief LOINC
Part Descriptions
LP420302-4 Daratumumab
Daratumumab is a biologic drug used to treat multiple myeloma. It is a IgG1k human monoclonal antibody directed against CD38, a molecule present on myeloma cells. By binding to CD38, it inhibits the growth of CD38 expressing tumor cells and causes cell death by immune mediated tumor cell lysis PMID: 29915586.
Source: Regenstrief LOINC
LP6336-4 Immunofixation
Plasma or concentrated urine is deposited on a gel. With an electrical current the proteins are sorted in function of their size, after which antigens for each targeted type of immunoglobulin are deposited on the gel. Thus more or less narrow bands appear on the gel, marking the location of the various immunoglobulines.
Immunofixation tends to replace protein electrophoresis because:
• it is faster (results within three hours);
• it is somewhat more sensitive. Immunofixation may reveal an immunoglobulin missed out by protein electrophoresis, especially at low concentrations (less than 1 gram/litre);
• it can be partially automated and can be used in more laboratories;
• it is more easily read and interpreted.
Immunofixation is however only sensitive to immunoglobulins and is more expensive than protein electrophoresis.
Copyright Text is available under the Creative Commons Attribution/Share-Alike License. See http://creativecommons.org/licenses/by-sa/3.0/ for details.
Source: Wikipedia, Immunofixation
Fully-Specified Name
- Component
- Daratumumab
- Property
- PrThr
- Time
- Pt
- System
- Ser
- Scale
- Ord
- Method
- Immunofixation
Additional Names
- Short Name
- Daratumumab Ser Ql IFE
- Display Name
- Daratumumab Immunofixation Ql (S)
- Consumer Name Alpha Get Info
- Daratumumab, Blood
Example Answer List: LL744-4
Source: Regenstrief Institute| Answer | Code | Score | Answer ID |
|---|---|---|---|
| Detected | LA11882-0 | ||
| Not detected | LA11883-8 |
Basic Attributes
- Class
- CHEM
- Type
- Laboratory
- First Released
- Version 2.69
- Last Updated
- Version 2.69
- Order vs. Observation
- Both
Language Variants Get Info
| Tag | Language | Translation |
|---|---|---|
| de-AT | German (Austria) | Synonyms: Daratumumab IF |
| es-ES | Spanish (Spain) | Daratumumab: |
| es-MX | Spanish (Mexico) | Daratumumab: |
| fr-FR | French (France) | Daratumumab: |
| it-IT | Italian (Italy) | Daratumumab: Synonyms: Chimica Presenza o Soglia Punto nel tempo (episodio) Siero |
| nl-NL | Dutch (Netherlands) | daratumumab: |
| zh-CN | Chinese (China) | 达雷妥尤单抗: Synonyms: IFE; |
LOINC Terminology Service (API) using HL7® FHIR® Get Info
Requests to this service require a free LOINC username and password. Below is a sample of the possible capabilities. See the LOINC Terminology Service documentation for more information.
- CodeSystem lookup
- https:
//fhir.loinc.org/CodeSystem/$lookup?system=http: //loinc.org&code=96420-5
LOINC Copyright
Copyright © 2024 Regenstrief Institute, Inc. All Rights Reserved. To the extent included herein, the LOINC table and LOINC codes are copyright